Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMP
Special Issues
Liquid Biopsy in Solid Tumors
share announcement

Liquid Biopsy in Solid Tumors

A special issue of Journal of Molecular Pathology (ISSN 2673-5261).

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 9780

Special Issue Editors

Dr. Umberto Malapelle

E-Mail Website
Guest Editor
Department of Public Health, University of Naples Federico II, Naples, Italy
Interests: predictive molecular pathology in solid tumors; next generation technologies in molecular biology; liquid biopsies; predictive oncology
Special Issues, Collections and Topics in MDPI journals
Dr. Francesco Passiglia

E-Mail Website
Guest Editor
Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy
Interests: non-small cell lung cancer

Special Issue Information

Dear Colleagues,

Liquid biopsies represent one of the most exciting revolutions of the predictive molecular pathology era. The term 'liquid biopsy' refers to test that are carried out on a number of different biological fluids, including but not limited to plasma, cefalorachidian liquid, effusions and urine. The application of next generation technology to liquid biopsies has allowed for a quantum leap in the detection and monitoring of different genetic alterations, and it has become one of the key weapons able to improve the clinical outcome of different cancer patients.

In this Special Issue, we would like to discuss new insights into the liquid biopsy landscape that may be useful to improve the diagnosis, prognosis and treatment of solid tumours, with a special focus on the application of next-generation technologies to different types of liquid biopsy-derived analytes.

Dr. Umberto Malapelle
Dr. Francesco Passiglia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Molecular Pathology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liquid biopsy
  • solid tumors
  • next-generation technologies
  • target treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

7 pages, 851 KiB  
Article
Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations
by Laura Melocchi, Michele Mondoni, Umberto Malapelle and Giulio Rossi
J. Mol. Pathol. 2022, 3(4), 286-292; https://doi.org/10.3390/jmp3040024 - 3 Nov 2022
Viewed by 2078
Abstract
Background: Smoking habit is a common cause of pulmonary Langerhans cell histiocytosis (PLCH) and lung cancer and both diseases may coexist in the lung and share genetic alterations, such as V600E BRAF mutations. We collected a small series of three cases of PLCH-associated [...] Read more.
Background: Smoking habit is a common cause of pulmonary Langerhans cell histiocytosis (PLCH) and lung cancer and both diseases may coexist in the lung and share genetic alterations, such as V600E BRAF mutations. We collected a small series of three cases of PLCH-associated lung adenocarcinoma in order to evaluate the molecular setup in both components and underline the critical role of careful tissue selection for predictive molecular driver testing. Methods: Three cases of PLCH-associated adenocarcinoma were collected from consultation files. Clinical data from referring physicians and clinical data were obtained. The surgical biopsies were tested by immunohistochemistry and molecular analysis after separate dissection of adenocarcinoma cells and Langerhans histiocytes. Results: There were three active smoking men with a median age at diagnosis of 60.6 years. PLCH was disclosed at imaging during work-up for suspected lung cancer. Molecular analysis revealed KRAS (G12C and G13C) mutations in two cases and V600E BRAF mutation in one case of PLCH. Immunostaining with the V600E BRAF mutation specific primary antibody VE1 correctly recognized BRAF-mutated LCH. One case was wild-type in both diseases. Two similar cases were found in the literature, one of which showed a discrepant KRAS (G12D) mutation in adenocarcinoma and a V600E BRAF mutation in LCH; Conclusions: This case series of PLCH-associated adenocarcinoma underline the possibility to disclose identical genetic alterations in co-existing benign and malignant pathologies, then potentially creating erroneous interpretation of molecular analysis leading to inadequate therapeutic options in case of incorrect diagnostic recognition and inappropriate selection of both components through microdissection. Full article
(This article belongs to the Special Issue Liquid Biopsy in Solid Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

28 pages, 1516 KiB  
Review
Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
by Marco Donatello Delcuratolo, Andrea Modrego-Sánchez, Maristella Bungaro, Beatriz Antón-Pascual, Santiago Teran, Valentina Dipace, Silvia Novello, Rocio Garcia-Carbonero, Francesco Passiglia and Cristina Graválos-Castro
J. Mol. Pathol. 2023, 4(3), 128-155; https://doi.org/10.3390/jmp4030013 - 5 Jul 2023
Viewed by 4500
Abstract
Colorectal cancer is one of the most prevalent cancers nowadays. In the metastatic setting, diagnosis and treatment have relied on tumor tissue analysis. However, the different limitations of this approach have recently opened the door to the introduction of liquid biopsy in the [...] Read more.
Colorectal cancer is one of the most prevalent cancers nowadays. In the metastatic setting, diagnosis and treatment have relied on tumor tissue analysis. However, the different limitations of this approach have recently opened the door to the introduction of liquid biopsy in the clinical setting. Liquid biopsy provides real-time information about the tumor and its heterogeneity in a simple, non-invasive, and repeatable way. There are several analytes that can be sought: exosomes, circulating tumor cells, and circulating tumor DNA, showing promising results in the areas of early detection, minimal residual disease, prognosis, or response to treatment. Here, we review the clinical applications of liquid biopsy in advanced colorectal cancer patients, focusing on metastatic diagnosis, prognostic assessment, drug sensitivity, treatment response, and acquired resistance monitoring. Full article
(This article belongs to the Special Issue Liquid Biopsy in Solid Tumors)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

8 pages, 276 KiB  
Opinion
Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting
by Luigi Della Gravara, Ciro Battiloro, Aniello Avellino, Francesca Caputo, Carmine D’Aniello and Danilo Rocco
J. Mol. Pathol. 2023, 4(2), 81-88; https://doi.org/10.3390/jmp4020009 - 30 Apr 2023
Viewed by 1994
Abstract
According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in EGFR+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfront treatment in this [...] Read more.
According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in EGFR+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfront treatment in this setting; therefore, this role has been scaled back in recent years. As of today, liquid biopsy has no ASCO or ESMO recommendation following first-line osimertinib; in the same vein, no targeted therapy has received ASCO or ESMO recommendation following post upfront Osimertinib progression. However, this standard could change in the near future. Therefore, adopting a clinical point of view, this paper aims to provide a comprehensive review on the previous, the current and the possible future role of liquid biopsy in the framework of the diagnostic–therapeutic algorithm of EGFR+ advanced NSCLC. Full article
(This article belongs to the Special Issue Liquid Biopsy in Solid Tumors)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop